POONGJEON PHARMACY CO., LTD.

As of June 30, 2026, POONGJEON PHARMACY CO., LTD. carries a market capitalization of 24.97B, placing it among publicly traded companies globally. Its enterprise value stands at 21.28B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, POONGJEON PHARMACY CO., LTD. has 8.84M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.48, and the price-to-book ratio stands at 0.77.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 21.28B versus a market cap of 24.97B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, POONGJEON PHARMACY CO., LTD. maintains a current ratio of 2.23, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.12, indicating elevated leverage, while an interest coverage ratio of -5.29 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, POONGJEON PHARMACY CO., LTD. posted a negative return on equity (ROE) of -20.72, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -15.35, reflecting losses generated across the asset base. The company generates approximately 1.52B in revenue per employee across its workforce of 32.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 25.45 indicates how many times POONGJEON PHARMACY CO., LTD. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, POONGJEON PHARMACY CO., LTD. recorded an income tax benefit of -378.03M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -6.25B and -5.87B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, POONGJEON PHARMACY CO., LTD.'s stock has declined approximately 57.40% over the past 52 weeks. The 50-day moving average sits at 2,410.40, while the 200-day moving average is 3,473.08.

Over the twelve months ended June 30, 2026, POONGJEON PHARMACY CO., LTD. generated 49.86B in revenue and converted that into -5.87B in net income, yielding earnings per share of -680.68. EBITDA reached -2.73B, while operating income came in at -4.58B.

As of June 30, 2026, POONGJEON PHARMACY CO., LTD. holds 10.51B in cash and equivalents against 6.82B in total debt, resulting in a net debt position of -1.03B. Total book value stands at 32.29B, with working capital of 16.52B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, POONGJEON PHARMACY CO., LTD. posted a gross margin of 22.33, reflecting its pricing power and cost economics. The operating margin of -9.19 and net profit margin of -11.77 provide insight into operational efficiency.

POONGJEON PHARMACY CO., LTD.'s most recent stock split took place on May 19, 2026 with a 5:1 split ratio.

As of June 30, 2026, POONGJEON PHARMACY CO., LTD. has an Altman Z-Score of -3.94, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.